Cargando…

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence

OBJECTIVES: Healthcare professionals (HCPs) with opioid dependence are at risk for relapse and death, particularly in the first year of recovery; however, maintenance treatment with opioid agonists is controversial in this safety-sensitive group. We evaluated long-term safety, tolerability, and trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Earley, Paul H., Zummo, Jacqueline, Memisoglu, Asli, Silverman, Bernard L., Gastfriend, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457834/
https://www.ncbi.nlm.nih.gov/pubmed/28358754
http://dx.doi.org/10.1097/ADM.0000000000000302
_version_ 1783241619307233280
author Earley, Paul H.
Zummo, Jacqueline
Memisoglu, Asli
Silverman, Bernard L.
Gastfriend, David R.
author_facet Earley, Paul H.
Zummo, Jacqueline
Memisoglu, Asli
Silverman, Bernard L.
Gastfriend, David R.
author_sort Earley, Paul H.
collection PubMed
description OBJECTIVES: Healthcare professionals (HCPs) with opioid dependence are at risk for relapse and death, particularly in the first year of recovery; however, maintenance treatment with opioid agonists is controversial in this safety-sensitive group. We evaluated long-term safety, tolerability, and treatment outcomes of injectable, intramuscular, extended-release naltrexone (XR-NTX) in opioid-dependent HCPs. METHODS: This single-arm, multisite, open-label study was conducted in opioid-dependent HCPs who had been detoxified from opioids for at least 2 weeks. Subjects received monthly XR-NTX injections for up to 24 months, combined with counseling via intensive outpatient substance abuse treatment programs. Assessments included monthly urine opioid drug tests and routine safety assessments, along with a trimonthly short form (36) Health Survey, opioid craving questionnaire, and Treatment Satisfaction Questionnaire for Medication. RESULTS: Of 49 opioid-dependent HCPs screened, 38 enrolled and received at least 1 XR-NTX injection. Most were female (n = 31) and nurses or nursing assistants (n = 30). More than half (n = 21; 55.3%) received at least 12 injections. Seven discontinued due to adverse events (3 anxiety, 2 headache, 1 injection-site mass, 1 derealization). None experienced relapses to opioid dependence necessitating detoxification, overdose, or death during treatment. At 24 months, mean opioid craving fell by 45.2%, and short form (36) mental component scores improved by 31.1% from baseline and approached normal levels. Of 22 unemployed subjects at baseline, 45.5% improved employment status at 24 months. CONCLUSIONS: Long-term (2 years) XR-NTX was associated with no new safety concerns, and, compared with shorter-term studies in the general population, similar or better rates of retention, opioid-negative urines, opioid craving reduction, mental health functional quality of life improvement, and re-employment.
format Online
Article
Text
id pubmed-5457834
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-54578342017-06-13 Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence Earley, Paul H. Zummo, Jacqueline Memisoglu, Asli Silverman, Bernard L. Gastfriend, David R. J Addict Med Original Research OBJECTIVES: Healthcare professionals (HCPs) with opioid dependence are at risk for relapse and death, particularly in the first year of recovery; however, maintenance treatment with opioid agonists is controversial in this safety-sensitive group. We evaluated long-term safety, tolerability, and treatment outcomes of injectable, intramuscular, extended-release naltrexone (XR-NTX) in opioid-dependent HCPs. METHODS: This single-arm, multisite, open-label study was conducted in opioid-dependent HCPs who had been detoxified from opioids for at least 2 weeks. Subjects received monthly XR-NTX injections for up to 24 months, combined with counseling via intensive outpatient substance abuse treatment programs. Assessments included monthly urine opioid drug tests and routine safety assessments, along with a trimonthly short form (36) Health Survey, opioid craving questionnaire, and Treatment Satisfaction Questionnaire for Medication. RESULTS: Of 49 opioid-dependent HCPs screened, 38 enrolled and received at least 1 XR-NTX injection. Most were female (n = 31) and nurses or nursing assistants (n = 30). More than half (n = 21; 55.3%) received at least 12 injections. Seven discontinued due to adverse events (3 anxiety, 2 headache, 1 injection-site mass, 1 derealization). None experienced relapses to opioid dependence necessitating detoxification, overdose, or death during treatment. At 24 months, mean opioid craving fell by 45.2%, and short form (36) mental component scores improved by 31.1% from baseline and approached normal levels. Of 22 unemployed subjects at baseline, 45.5% improved employment status at 24 months. CONCLUSIONS: Long-term (2 years) XR-NTX was associated with no new safety concerns, and, compared with shorter-term studies in the general population, similar or better rates of retention, opioid-negative urines, opioid craving reduction, mental health functional quality of life improvement, and re-employment. Lippincott Williams & Wilkins 2017-05 2017-03-29 /pmc/articles/PMC5457834/ /pubmed/28358754 http://dx.doi.org/10.1097/ADM.0000000000000302 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Original Research
Earley, Paul H.
Zummo, Jacqueline
Memisoglu, Asli
Silverman, Bernard L.
Gastfriend, David R.
Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
title Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
title_full Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
title_fullStr Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
title_full_unstemmed Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
title_short Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
title_sort open-label study of injectable extended-release naltrexone (xr-ntx) in healthcare professionals with opioid dependence
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457834/
https://www.ncbi.nlm.nih.gov/pubmed/28358754
http://dx.doi.org/10.1097/ADM.0000000000000302
work_keys_str_mv AT earleypaulh openlabelstudyofinjectableextendedreleasenaltrexonexrntxinhealthcareprofessionalswithopioiddependence
AT zummojacqueline openlabelstudyofinjectableextendedreleasenaltrexonexrntxinhealthcareprofessionalswithopioiddependence
AT memisogluasli openlabelstudyofinjectableextendedreleasenaltrexonexrntxinhealthcareprofessionalswithopioiddependence
AT silvermanbernardl openlabelstudyofinjectableextendedreleasenaltrexonexrntxinhealthcareprofessionalswithopioiddependence
AT gastfrienddavidr openlabelstudyofinjectableextendedreleasenaltrexonexrntxinhealthcareprofessionalswithopioiddependence